Digital Look

Welcome to Digital Look++,
you are not logged in

AstraZeneca (AZN)

Pharma and Biotech

10,002.00p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
30-Sep-24	Interim	13,565.00	1,828.00	92.00¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-19	24,384.00	1,548.00	103.00¢	93.4	n/a	-39%	280.00¢	2.9%
31-Dec-20	26,617.00	3,916.00	244.00¢	37.9	0.3	+137%	280.00¢	3.0%
31-Dec-21	37,417.00	(265.00)	8.00¢	1,371.3	n/a	-97%	287.00¢	2.6%
31-Dec-22	44,351.00	2,501.00	212.00¢	66.9	0.0	+2,550%	290.00¢	2.0%
31-Dec-23	45,811.00	6,899.00	384.00¢	34.9	0.4	+81%	290.00¢	2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-24	52,506.01	15,651.61	630.61p	15.8	0.1	+108%	247.02p	0.0%
31-Dec-25	56,662.22	17,747.05	725.34p	13.7	0.9	+15%	259.29p	0.0%
31-Dec-26	59,880.19	19,902.57	824.30p	12.1	0.9	+14%	272.59p	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	97.94	35.16	341.02	0.10

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.